Quantcast
Last updated on April 17, 2014 at 16:32 EDT

Latest Erythropoietin Stories

2012-01-20 10:45:38

Drugs that treat anemia are critical for many who have kidney disease Highlights     More than 20 million adults in the United States have chronic kidney disease.     Drugs that treat red blood cell deficiencies are critical for maintaining many chronic kidney disease patients' health.     Experts comment on newly released federal recommendations for these drugs. The U.S. Food and Drug Administration (FDA) recently recommended that...

2012-01-09 14:00:00

LAKE FOREST, Ill., Jan. 9, 2012 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced enrollment of the first patient in a Phase III U.S. clinical program for its biosimilar erythropoietin (EPO). Hospira's Phase III program, which follows a successful Phase I trial that concluded last year, will compare safety and efficacy of Hospira's EPO and the reference product, Amgen's Epogen(®) in patients...

2011-12-23 08:58:26

Anemia drugs prevent many transplanted kidneys from failing Correcting anemia, a red blood cell deficiency, can preserve kidney function in many kidney transplant recipients, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results indicate that aggressively treating anemia may help save the kidneys–and possibly the lives–of many transplant recipients. Anemia commonly arises in patients with kidney disease...

2011-12-15 15:00:00

MADISON, Wis., Dec. 15, 2011 /PRNewswire/ -- Aldevron to generate antibodies for erythropoietin research consortium. Aldevron is pleased to announce its participation in a new three year, $5.4 million research project to study the long-term risks of erythropoietin (EPO) and its derivatives (epoetins) in cancer patients. EPO is commonly used to treat anemia related to cancer and cardiovascular surgery. This project funded by the European Union is coordinated by Dr. Drorit...

2011-12-15 12:08:47

New England Journal of Medicine study could change clinical practice, help vulnerable patients avoid transfusion risks More than half of the older, anemic patients in a New England Journal of Medicine study did not need blood transfusions as they recovered from hip surgery, according to new research co-authored by University of Maryland School of Medicine scientists. The findings could immediately change the way such patients are treated. Doctors have long assumed that transfusions...

2011-12-12 10:37:31

New research in the FASEB Journal suggests that EPO poses a risk to blood vessels in the brain and body Erythropoietin or EPO might be considered a "performance enhancing" substance for athletes, but new research published online in The FASEB Journal (http://www.fasebj.org) shows that these enhancements come at a high cost--increased risk of vascular problems in the brain. According to the study, short- or long-term use of EPO raises blood pressure by constricting arteries, which reduces...

2011-12-08 07:15:00

SAN FRANCISCO, Dec. 8, 2011 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported that its partner Affymax, Inc. announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 15 to 1, with 1 abstention, that peginesatide demonstrated a favorable benefit/risk profile for use in the treatment of dialysis patients with anemia due to chronic kidney disease (CKD). Nektar and Affymax have an exclusive agreement under which Nektar...

2011-11-15 15:39:00

System combining gene therapy with tissue engineering could avoid the need for frequent injections of recombinant drugs BOSTON, Nov. 15, 2011 /PRNewswire-USNewswire/ -- Patients who rely on recombinant, protein-based drugs must often endure frequent injections, often several times a week, or intravenous therapy. Researchers at Children's Hospital Boston demonstrate the possibility that blood vessels, made from genetically engineered cells, could secrete the drug on demand directly into...

2011-11-14 07:30:00

NEW YORK, Nov. 14, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that two posters highlighting potential cost savings based on observations from previous clinical trials of Zerenex(TM) (ferric citrate) were presented by DaVita Clinical Research this past weekend during the American Society of Nephrology (ASN) Kidney Week 2011 Annual Meeting and Exposition in Philadelphia. Zerenex, an oral, ferric iron-based drug candidate, is currently in Phase 3...

2011-10-11 06:30:00

NES-ZIONA, Israel, Oct. 11, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH) today announced that it received a notice of allowance from the U.S. Patent and Trademark Office (PTO) for a patent application covering PROLOR's CTP-modified interferons. Interferons are proteins produced in response to the presence of tumor cells or pathogens, such as viruses, bacteria and parasites. Several interferon proteins, including interferon alfa and beta, are used as therapies for hepatitis B...